vs

Side-by-side financial comparison of Foresight Autonomous Holdings Ltd. (FRSX) and SELLAS Life Sciences Group, Inc. (SLS). Click either name above to swap in a different company.

Foresight Autonomous Holdings Ltd. is the larger business by last-quarter revenue ($128.0K vs $79.0K, roughly 1.6× SELLAS Life Sciences Group, Inc.). Foresight Autonomous Holdings Ltd. runs the higher net margin — -2155.5% vs -12108.9%, a 9953.4% gap on every dollar of revenue.

Foresight Autonomous Holdings Ltd. develops and markets advanced perception systems for the autonomous driving and automotive safety sectors. Its core offerings include multi-sensor vision solutions combining thermal imaging, visible light and AI analytics to enhance obstacle detection, collision avoidance and navigation reliability for passenger cars, commercial fleets and off-road industrial equipment, with operations spanning North America, Europe and Asia.

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative cancer immunotherapies for patients with unmet medical needs. Its core pipeline targets both hematological malignancies and solid tumors, with lead product candidates addressing indications like acute myeloid leukemia, primarily serving markets across North America.

FRSX vs SLS — Head-to-Head

Bigger by revenue
FRSX
FRSX
1.6× larger
FRSX
$128.0K
$79.0K
SLS
Higher net margin
FRSX
FRSX
9953.4% more per $
FRSX
-2155.5%
-12108.9%
SLS

Income Statement — Q2 FY2025 vs Q1 FY2024

Metric
FRSX
FRSX
SLS
SLS
Revenue
$128.0K
$79.0K
Net Profit
$-2.8M
$-9.6M
Gross Margin
67.2%
Operating Margin
-2305.5%
-12208.9%
Net Margin
-2155.5%
-12108.9%
Revenue YoY
4.1%
Net Profit YoY
13.0%
13.8%
EPS (diluted)
$-0.01
$-0.21

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRSX
FRSX
SLS
SLS
Q2 25
$128.0K
Q2 24
$123.0K
Q1 24
$79.0K
Q2 22
$213.0K
Net Profit
FRSX
FRSX
SLS
SLS
Q2 25
$-2.8M
Q2 24
$-3.2M
Q1 24
$-9.6M
Q2 22
$-10.1M
Gross Margin
FRSX
FRSX
SLS
SLS
Q2 25
67.2%
Q2 24
69.1%
Q1 24
Q2 22
57.7%
Operating Margin
FRSX
FRSX
SLS
SLS
Q2 25
-2305.5%
Q2 24
-2602.4%
Q1 24
-12208.9%
Q2 22
-1936.6%
Net Margin
FRSX
FRSX
SLS
SLS
Q2 25
-2155.5%
Q2 24
-2578.9%
Q1 24
-12108.9%
Q2 22
-4749.3%
EPS (diluted)
FRSX
FRSX
SLS
SLS
Q2 25
$-0.01
Q2 24
$-0.01
Q1 24
$-0.21
Q2 22
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRSX
FRSX
SLS
SLS
Cash + ST InvestmentsLiquidity on hand
$6.4M
$18.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$5.9M
$9.7M
Total Assets
$8.5M
$24.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRSX
FRSX
SLS
SLS
Q2 25
$6.4M
Q2 24
$12.0M
Q1 24
$18.4M
Q2 22
$35.5M
Stockholders' Equity
FRSX
FRSX
SLS
SLS
Q2 25
$5.9M
Q2 24
$10.9M
Q1 24
$9.7M
Q2 22
$37.1M
Total Assets
FRSX
FRSX
SLS
SLS
Q2 25
$8.5M
Q2 24
$15.4M
Q1 24
$24.4M
Q2 22
$41.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRSX
FRSX
SLS
SLS
Operating Cash FlowLast quarter
$-2.6M
$-10.8M
Free Cash FlowOCF − Capex
$-2.6M
FCF MarginFCF / Revenue
-2041.4%
Capex IntensityCapex / Revenue
2.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRSX
FRSX
SLS
SLS
Q2 25
$-2.6M
Q2 24
$-2.5M
Q1 24
$-10.8M
Q2 22
$-3.3M
Free Cash Flow
FRSX
FRSX
SLS
SLS
Q2 25
$-2.6M
Q2 24
$-2.6M
Q1 24
Q2 22
$-3.3M
FCF Margin
FRSX
FRSX
SLS
SLS
Q2 25
-2041.4%
Q2 24
-2080.5%
Q1 24
Q2 22
-1571.8%
Capex Intensity
FRSX
FRSX
SLS
SLS
Q2 25
2.3%
Q2 24
17.1%
Q1 24
Q2 22
32.9%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons